<DOC>
	<DOC>NCT01536223</DOC>
	<brief_summary>Locally advanced nasopharyngeal carcinoma patients(UICC7th stageIII to IVb) will receive either cisplatin plus 5-fluorouracil (PF) or docetaxel plus cisplatin and 5-fluorouracil(TPF) neoadjuvant chemotherapy with concurrent chemoradiation.</brief_summary>
	<brief_title>Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>For locally advanced nasopharyngeal carcinoma patients(UICC7th stageIII to IVb),the investigators randomised assign to either 3 cycles of cisplatin plus 5-fluorouracil plus (PF) or 3 cycles of docetaxel plus cisplatin and 5-fluorouracil(TPF) neoadjuvant chemotherapy. 21 days a cycle. After the neoadjuvant chemotherapy ,the patients will receive the intensity modulated radiotherapy(IMRT) with 2 cycles of concurrent chemotherapy of cisplatin 80mg/m2.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1. Patients with newly histologically confirmed nonkeratinizing carcinoma. 2. Tumor staged as N23 or T34N1(according to the 7th AJCC staging system) 3. No evidence of distant metastasis(M0) 4. Performance status:KPS&gt;70 5. With normal liver function test(ALT, AST&lt;1.5ULN) 6. Renal:creatinine clearance &gt;60ml/min 7. Without hematopathy,marrow:WBC&gt;4*109/L, HGB&gt;80G/L, and PLT&gt;100*109/L. 8. With controled blood glucose for diabetes patients 9. Written informed consent 1. WHO type I squamous cell carcinoma or adenocarcinoma 2. Age&gt;70 or &lt;18 3. With a history of renal disease 4. Prior malignancy (except adequately treated carcinoma insitu of the cervix or basal/squamous cell carcinoma of the skin0 5. Previous chemotherapy or radiotherapy(except nonmelanomatous skin cancers outside the intended RT treatment volume) 6. Patient is pregnant or lactating . 7. Peripheral neuropathy 8. Emotional disturbance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Nasopharyngeal Carcinoma (NPC)</keyword>
	<keyword>cisplatin and 5-fluorouracil (PF)</keyword>
	<keyword>docetaxel,cisplatin and 5-fluorouracil(TPF)</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>intensity modulated radiotherapy(IMRT)</keyword>
</DOC>